Press Releases

Date	Title	Format
April 11, 2023	Chinook Therapeutics to Present at Upcoming Investor Conferences	PDF Version
April 11, 2023	Chinook Therapeutics Announces Voluntary Pause in Dosing of CHK-336 in Ongoing Phase 1 Clinical Trial in Healthy Volunteers	PDF Version
April 7, 2023	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
March 28, 2023	Chinook Therapeutics to Present at the Guggenheim Healthcare Talks \| Genomic Medicines and Rare Disease Days	PDF Version
March 23, 2023	Chinook Therapeutics Announces Upcoming Presentations at ISN World Congress of Nephrology 2023	PDF Version
March 7, 2023	Chinook Therapeutics to Present at the Oppenheimer 33rd Annual Healthcare Conference	PDF Version
March 3, 2023	Chinook Therapeutics Announces New Employment Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)	PDF Version
February 28, 2023	Chinook Therapeutics Announces Upcoming Presentations at the 5th Chronic Kidney Disease Drug Development Summit	PDF Version
February 27, 2023	Chinook Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Updates	PDF Version
February 15, 2023	Chinook Therapeutics Announces the Appointment of Andrew Oxtoby as Chief Commercial Officer	PDF Version

Investors